Features of the course of cardiovascular pathology and type 2 diabetes mellitus in patients with COVID-19


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Acute respiratory viral diseases, including coronavirus disease, cause the progression of pre-existing chronic non-infectious diseases, including cardiovascular diseases (CVD) and type 2 diabetes mellitus (DM). The emergence of life-threatening complications against the background of a new coronavirus infection makes it necessary to study the features of the course of cardiovascular pathology and type 2 diabetes mellitus in conditions of this pathology. The regularities of the course of CVD and DM, as well as the development of complications in patients with COVID-19, are currently not completely established. The article provides an overview of the literature on the features of the course of cardiovascular pathology and type 2 diabetes mellitus in patients with COVID-19. The issue of the possibility of using drug therapy in patients with cardiovascular diseases, type 2 diabetes mellitus and COVID-19 is being discussed.

全文:

受限制的访问

作者简介

E. Polozova

National Research Ogarev Mordovia State University

MD

V. Skvortsov

Volgograd State Medical University

Email: vskvortsov1@ya.ru
MD

L. Chegodaeva

National Research Ogarev Mordovia State University

Candidate of Medical Sciences

N. Kurkina

National Research Ogarev Mordovia State University

Candidate of Medical Sciences

T. Prokhorova

National Research Ogarev Mordovia State University

N. Al-Zakhar

National Research Ogarev Mordovia State University

N. Nefedov

National Research Ogarev Mordovia State University

参考

  1. Беликина Д.В., Малышева Е.С., Петров А.В. и др. COVID-19 при сопутствующем сахарном диабете: особенности клинического течения, метаболизма, воспалительных и коагуляционных нарушений. Современные технологии в медицине. 2020; 12 (5): 6-18 [Belikina D.V., Malysheva E.S., Petrov A.V. et al. COVID-19 in patients with diabetes: clinical course, metabolic status, inflammation, and coagulation disorder. Sovremennye tehnologii vmedicine. 2020; 12 (5): 6-18 (in Russ.)]. https://doi.org/10.17691/stm2020.12.5.01
  2. Schiffrin E.L., Flack J.M., Ito S. et al. Hypertension and COVID-19. Am J. Hypertens. 2020; 33 (5): 373-4. doi: 10.1093/ajh/hpaa057
  3. Жмеренецкий К.В., Витько А.В., Петричко Т.А. и др. Сложные вопросы ведения пациентов с COVID-19, коморбидных по сердечно-сосудистым заболеваниям и сахарному диабету 2-го типа. Дальневосточный медицинский журнал. 2020; 2: 102-14 doi: 10.35177/1994-5191-20202-101-113
  4. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020; 14 (3): 247-50. doi: 10.1016/j.dsx.2020.03.013
  5. Старшинова А.А., Кушнарева Е.А., Малкова А.М. и др. Новая коронавирусная инфекция: особенности клинического течения, возможности диагностики, лечения и профилактики инфекции у взрослых и детей. Вопросы современной педиатрии. 2020; 19 (2): 123-31 [Starshinova A.A., Kushnareva E.A., Malkova A.M. et al. New Coronaviral Infection: Features of Clinical Course, Capabilities of Diagnostics, Treatment and Prevention in Adults and Children. Current Pediatrics. 2020; 19 (2): 123-31 (in Russ.)]. https://doi.org/10.15690/vsp. v19i2.2105
  6. Ойноткинова О.Ш., Ларина В.Н., Зайратьянц О.В. Осложнения со стороны сердечно-сосудистой системы при COVID-19. Московская медицина. 2020; 3 (37): 80-9
  7. Kreutz R., Algharably E.A., Azizi M. et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020; 116 (10): 1688-99. doi: 10.1093/cvr/cvaa097
  8. Cole J.E., Park I., Ahern D.J. et al. Immune cell census in murine atherosclerosis: cytometry by time of fl ight illuminates vascular myeloid cell diversity. Cardiovasc Res. 2018; 114 (10): 1360-71. doi: 10.1093/cvr/cvy109
  9. Matysiak-Budnik T., Heyman M., Megraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003; 18 (Suppl. 1): 55-62. doi: 10.1046/j.1365-2036.18.s1.6.x
  10. Lin L., Jiang X., Zhang Z. at al. Gastrointestinal Symptoms of 95 Cases With SARS-CoV-2 Infection. Gut. 2020; 69 (6): 997-1001. DOI: 10.1136/ gutjnl-2020-321013
  11. Shim S., Jang H.S., Myung H.W. et al. Rebamipide ameliorates radiation-induced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017; 15 (329): 40-7. doi: 10.1016/j.taap.2017.05.012
  12. Liu K., Fang Y.Y., Deng Y. et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. (Engl). 2020; 133 (9): 1025-31. doi: 10.1097/CM9.0000000000000744
  13. Шестакова М.В., Викулова О.К., Исаков М.А. и др. Сахарный диабет и COVID-19: анализ клинических исходов по данным регистра сахарного диабета Российской Федерации. Проблемы эндокринологии. 2020; 66 (1): 35-46 [Shestakova M.V., Vikulova O.K., Isakov М.А. et al. Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the russian diabetes registry. Problems of Endocrinology. 2020; 66 (1): 35-46 (in Russ.)]. https://doi. org/10.14341/probl12458
  14. Wang A., Zhao W., Xu Z. et al. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract. 2020; 162: 108-18. doi: 10.1016/j.diabres.2020.108118
  15. Zhou F., Zhang Y., Chen J. et al. Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice. Eur J. Pharmacol. 2016; 791: 735-40. doi: 10.1016/j.ejphar.2016.10.016
  16. Kohio H.P., Adamson A.L. Glycolytic control of vacuolar-type ATPase activity: a mechanism to regulate influenza viral infection. Virology. 2013; 444 (1-2): 301-9. doi: 10.1016/j.virol.2013.06.026
  17. Gupta R., Ghosh A., Singh A.K. et al. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020; 14 (3): 211-2. doi: 10.1016/j.dsx.2020.03.002

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##